Johnson & Johnson (ETR:JNJ)
163.32
-0.02 (-0.01%)
Oct 31, 2025, 5:35 PM CET
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
€570,643
Profits / Employee
€155,552
Market Cap
394.52B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 72,000 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,730 |
Johnson & Johnson News
- 4 hours ago - Best Dividend Aristocrats For November 2025 - Seeking Alpha
- 20 hours ago - Johnson & Johnson (JNJ) Seeks FDA Approval for Expanded Use of Stelara - GuruFocus
- 1 day ago - The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage - Nasdaq
- 1 day ago - Top Analyst Reports for Broadcom, Johnson & Johnson and Palantir - Nasdaq
- 2 days ago - Noteworthy ETF Inflows: SPXL, JNJ, ABBV, HD - Nasdaq
- 3 days ago - Johnson & Johnson (JNJ) Faces Lawsuit Over Tylenol Marketing Practices - GuruFocus
- 3 days ago - Johnson & Johnson (JNJ) Initiates Pioneering Study on gMG Treatment - GuruFocus
- 3 days ago - JNJ Factor-Based Stock Analysis - Nasdaq